NCT06350825

Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients

Evaluating the Efficacy and Safety of Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: The First Affiliated Hospital with Nanjing Medical University · Academic / Other
• Sex: Male
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate: The radiographic progression-free survival (rPFS) of metastatic hormone-sensitive prostate cancer (mHSPC) patients treated with androgen deprivation therapy (ADT) + second-generation antiandrogens±chemotherapy combined with cytoreductive prostatectomy (CRP)

Detailed description

To investigate the multimodality approaches for mHSPC

Conditions

• Metastatic Prostate Cancer
• Therapy, Directly Observed

Interventions

Type	Name	Description
PROCEDURE	Cytoreductive prostatectomy or brachytherapy	local treatment+SOC for metastatic prostate cancer
DRUG	ADT+second-generation antiandrogens ± chemotherapy	SOC(Triplet or doublet therapy) for mHSPC

Timeline

• Start date: 2016-01-01
• Primary completion: 2027-12-31
• Completion: 2028-12-31
• First posted: 2024-04-05
• Last updated: 2024-04-05

Locations

1 site across 1 country: China